|Bid||16.90 x 900|
|Ask||17.09 x 800|
|Day's Range||16.51 - 17.32|
|52 Week Range||2.81 - 17.33|
|Beta (5Y Monthly)||0.15|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 04, 2020 - Nov 09, 2020|
|Forward Dividend & Yield||0.01 (0.06%)|
|Ex-Dividend Date||Jun 12, 2020|
|1y Target Est||10.42|
Owens & Minor (OMI) delivered earnings and revenue surprises of 5.26% and -4.77%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Owens & Minor (NYSE:OMI) increased 2.89% in after-market trading after the company reported Q2 results.Quarterly Results Earnings per share were up 100.00% year over year to $0.20, which beat the estimate of $0.19.Revenue of $1,808,000,000 decreased by 27.21% from the same period last year, which missed the estimate of $1,920,000,000.Looking Ahead Earnings guidance hasn't been issued by the company for now.Revenue guidance hasn't been issued by the company for now.How To Listen To The Conference Call Date: Aug 04, 2020View more earnings on OMITime: 04:30 PMET Webcast URL: https://edge.media-server.com/mmc/p/xh4wo6msTechnicals 52-week high: $17.3352-week low: $2.75Price action over last quarter: Up 141.43%Company Overview Owens & Minor distributes consumable medical supplies to a variety of providers. The company operates in two segments that are Global products and Global Solutions. The company offers a portfolio of products and services to healthcare providers and manufacturers in the Global solutions segment. In the Global product segment, the company manufactures and sources medical-surgical products through our production and kitting operations. The majority of the revenue is generated from the Global solutions segment. The company operates in Asia, Europe, Latin America, and the United States, while the majority of revenue comes from the United States.See more from Benzinga * Stocks That Hit 52-Week Highs On Monday * Stocks That Hit 52-Week Highs On Tuesday * Stocks That Hit 52-Week Highs On Monday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Dismal economic data that pressured the entire market at the end of July rolled right off the backs of some high-flying healthcare stocks. Here's what sent their share prices screaming higher. This clinical-stage biotechnology company doesn't have any products to sell yet, but Altimmune's attempt to develop a single-dose intranasal coronavirus vaccine is getting lots of attention.